Ivosidenib

Ivosidenib
Clinical data
Routes of
administration		 Oral
ATC code
  • None
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
Formula C28H22ClF3N6O3
Molar mass 582.97 g·mol−1
3D model (JSmol)

Ivosidenib is an experimental drug for treatment of cancer. It is a small molecule inhibitor of IDH1, which is mutated in several forms of cancer. The drug is being developed by Agios Pharmaceuticals and is in phase III clinical trials. The FDA awarded orphan drug status for acute myeloid leukemia and cholangiocarcinoma.[1]

Ivosidenib was approved by the FDA for acute myeloid leukemia (AML) with an IDH1 mutation and is presently in a phase III clinical trial for cholangiocarcinoma with an IDH1 mutation.[2] Ivosidenib was the first anticancer therapy to approved for patients with a specific genetic variant (citation needed).

References

  1. ↑ http://adisinsight.springer.com/drugs/800040155
  2. ↑ Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Patients With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation (AGILE)
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.